These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20811684)

  • 21. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
    Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
    Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of epithelial-mesenchymal transition in bladder cancer cells via modulation of mTOR signalling.
    Iskender B; Izgi K; Hizar E; Jauch J; Arslanhan A; Yuksek EH; Canatan H
    Tumour Biol; 2016 Jun; 37(6):8281-91. PubMed ID: 26718217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of HMGA2 in bladder cancer and its association with epithelial-to-mesenchymal transition.
    Ding X; Wang Y; Ma X; Guo H; Yan X; Chi Q; Li J; Hou Y; Wang C
    Cell Prolif; 2014 Apr; 47(2):146-51. PubMed ID: 24571540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Krüppel-like factor 4 is a novel prognostic predictor for urothelial carcinoma of bladder and it regulates TWIST1-mediated epithelial-mesenchymal transition.
    Tseng WC; Chuang CW; Yang MH; Pan CC; Tarng DC
    Urol Oncol; 2016 Nov; 34(11):485.e15-485.e24. PubMed ID: 27519276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model.
    Choi S; Sano D; Cheung M; Zhao M; Jasser SA; Ryan AJ; Mao L; Chen WT; El-Naggar AK; Myers JN
    Clin Cancer Res; 2008 Aug; 14(16):5081-9. PubMed ID: 18698025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
    Naumov GN; Nilsson MB; Cascone T; Briggs A; Straume O; Akslen LA; Lifshits E; Byers LA; Xu L; Wu HK; Jänne P; Kobayashi S; Halmos B; Tenen D; Tang XM; Engelman J; Yeap B; Folkman J; Johnson BE; Heymach JV
    Clin Cancer Res; 2009 May; 15(10):3484-94. PubMed ID: 19447865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ionizing radiation promotes advanced malignant traits in nasopharyngeal carcinoma via activation of epithelial-mesenchymal transition and the cancer stem cell phenotype.
    Su Z; Li G; Liu C; Ren S; Tian Y; Liu Y; Qiu Y
    Oncol Rep; 2016 Jul; 36(1):72-8. PubMed ID: 27108809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quercetin reverses EGF-induced epithelial to mesenchymal transition and invasiveness in prostate cancer (PC-3) cell line via EGFR/PI3K/Akt pathway.
    Bhat FA; Sharmila G; Balakrishnan S; Arunkumar R; Elumalai P; Suganya S; Raja Singh P; Srinivasan N; Arunakaran J
    J Nutr Biochem; 2014 Nov; 25(11):1132-1139. PubMed ID: 25150162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.
    Guérin O; Etienne-Grimaldi MC; Monteverde M; Sudaka A; Brunstein MC; Formento P; Lattanzio L; Maffi M; Tonissi F; Ortholan C; Pagès G; Fischel JL; Lo Nigro C; Merlano M; Milano G
    Urol Oncol; 2013 Nov; 31(8):1567-75. PubMed ID: 22608542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic Potential of Regorafenib in Cisplatin-Resistant Bladder Cancer with High Epithelial-Mesenchymal Transition and Stemness Properties.
    Kuan FC; Li JM; Huang YC; Chang SF; Shi CS
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy.
    Adam L; Zhong M; Choi W; Qi W; Nicoloso M; Arora A; Calin G; Wang H; Siefker-Radtke A; McConkey D; Bar-Eli M; Dinney C
    Clin Cancer Res; 2009 Aug; 15(16):5060-72. PubMed ID: 19671845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COX-2 potentiates cisplatin resistance of non-small cell lung cancer cells by promoting EMT in an AKT signaling pathway-dependent manner.
    Jiang GB; Fang HY; Tao DY; Chen XP; Cao FL
    Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3838-3846. PubMed ID: 31115011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CAV-1 contributes to bladder cancer progression by inducing epithelial-to-mesenchymal transition.
    Liang W; Hao Z; Han JL; Zhu DJ; Jin ZF; Xie WL
    Urol Oncol; 2014 Aug; 32(6):855-63. PubMed ID: 24968949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
    Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma.
    Klein JD; Christopoulos A; Ahn SM; Gooding WE; Grandis JR; Kim S
    Head Neck; 2012 Sep; 34(9):1269-76. PubMed ID: 22307735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma.
    Nakajima S; Doi R; Toyoda E; Tsuji S; Wada M; Koizumi M; Tulachan SS; Ito D; Kami K; Mori T; Kawaguchi Y; Fujimoto K; Hosotani R; Imamura M
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4125-33. PubMed ID: 15217949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stereospecific effects of ginsenoside 20-Rg3 inhibits TGF-β1-induced epithelial-mesenchymal transition and suppresses lung cancer migration, invasion and anoikis resistance.
    Kim YJ; Choi WI; Jeon BN; Choi KC; Kim K; Kim TJ; Ham J; Jang HJ; Kang KS; Ko H
    Toxicology; 2014 Aug; 322():23-33. PubMed ID: 24793912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Establishment of a bladder cancer cell line expressing both mesenchymal and epithelial lineage-associated markers.
    Zareinejad M; Faghih Z; Ariafar A; Safaei A; Ghaderi A
    Hum Cell; 2021 Mar; 34(2):675-687. PubMed ID: 33165868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
    Yue P; Zhang X; Paladino D; Sengupta B; Ahmad S; Holloway RW; Ingersoll SB; Turkson J
    Oncogene; 2012 May; 31(18):2309-22. PubMed ID: 21909139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GP73 promotes invasion and metastasis of bladder cancer by regulating the epithelial-mesenchymal transition through the TGF-β1/Smad2 signalling pathway.
    Yang HJ; Liu GL; Liu B; Liu T
    J Cell Mol Med; 2018 Mar; 22(3):1650-1665. PubMed ID: 29349903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.